Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Benjamin Hickey, President of RayzeBio Org. at Bristol Myers Squibb Co. (NYSE:BMY), recently sold shares valued at $3,701. The transaction, which took place on May 9, 2025, involved the sale of 97.391 shares at a price of $38.01 each. The stock currently trades at $46.59, with InvestingPro analysis indicating the company is undervalued. BMY maintains a strong dividend yield of 5.32% and has consistently paid dividends for 55 consecutive years. These shares were indirectly owned and sold by Hickey’s spouse, marking a complete disposition of the stock fund units held by the spouse. Following this transaction, Hickey holds 8,789 shares directly. The company maintains a GOOD financial health score according to InvestingPro, which offers 8 additional key insights about BMY’s financial performance and growth potential in its comprehensive Pro Research Report.
In other recent news, Bristol Myers Squibb reported impressive financial results for the first quarter of 2025, with earnings per share (EPS) of $1.80, surpassing analysts’ expectations of $1.52. The company’s revenue reached $11.2 billion, exceeding the anticipated $10.68 billion, highlighting strong demand across its growth portfolio. In a strategic move, Bristol Myers Squibb appointed Cari Gallman as the new Executive Vice President, General Counsel, and Chief Policy Officer, following the retirement of Sandra Leung. Gallman, who has been with the company for a decade, will oversee the law department and manage areas such as intellectual property and compliance.
Additionally, BofA Securities increased its price target for Bristol Myers Squibb to $56 from $54, maintaining a Neutral rating, citing the company’s valuation alignment with its peers. Despite the earnings beat, the company faces challenges from generic competition, which could impact growth in the coming years. Bristol Myers Squibb also raised its full-year revenue guidance to a range of $45.8-$46.8 billion, reflecting strong performance and favorable foreign exchange impacts. The company remains focused on its strategic priorities, including maximizing its growth portfolio and advancing its R&D pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.